• Citer

A phase I study of BAY 43-9006, a novel Raf kinase and VEGFR inhibitor, in combination with taxotere in patients with advanced, solid tumors

par Awada, Ahmad ;Hendlisz, Alain ;Gil, Thierry ;Schwartz, Bertrand ;Bartholomeus, Sylvie;de Valeriola, Dominique ;Brendel, Erich;Haase, Claus Gert;Piccart-Gebhart, Martine
Référence 16th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics(2004), European Journal of Cancer, Vol. 2, page (114)
Publication Publié, 2004

Publication dans des actes

• Détails

Titre:	A phase I study of BAY 43-9006, a novel Raf kinase and VEGFR inhibitor, in combination with taxotere in patients with advanced, solid tumors
Auteur:	Awada, Ahmad; Hendlisz, Alain; Gil, Thierry; Schwartz, Bertrand; Bartholomeus, Sylvie; de Valeriola, Dominique; Brendel, Erich; Haase, Claus Gert; Piccart-Gebhart, Martine
Informations sur la publication:	16th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics(2004), European Journal of Cancer, Vol. 2, page (114)
Statut de publication:	Publié, 2004
Sujet CREF:	Cancérologie
	Pharmacologie
Langue:	Anglais